<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533612455203</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533612455203</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Perioperative Nutrition Support in Cancer Patients</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huhmann</surname><given-names>Maureen B.</given-names></name>
<degrees>DCN, RD, CSO</degrees>
<xref ref-type="aff" rid="aff1-0884533612455203">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>August</surname><given-names>David A.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-0884533612455203">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533612455203"><label>1</label>Department of Nutritional Science</aff>
<aff id="aff2-0884533612455203"><label>2</label>Department of Surgery, Division of Surgical Oncology, The Cancer Institute of New Jersey and UMDNJ/Robert Wood Johnson Medical School, New Brunswick, NJ</aff>
<author-notes>
<corresp id="corresp1-0884533612455203">Maureen B. Huhmann, DCN, RD, CSO, Adjunct Assistant Professor, Department of Nutritional Science, University of Medicine and Dentistry of New Jersey, 65 Bergen St, Newark, NJ 07107, USA; e-mail: <email>huhmanma@umdnj.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<issue-title>Nutrition and Cancer</issue-title>
<fpage>586</fpage>
<lpage>592</lpage>
<permissions>
<copyright-statement>© 2012 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Malnutrition and weight loss negatively affect outcomes in surgical cancer patients. Decades of research have sought to identify the most appropriate use of nutrition support in these patients. National and international guidelines help to direct clinicians’ use of nutrition support in surgical patients, but a number of specific issues concerning the use of nutrition support continue to evolve. This review focuses on 5 key issues related to perioperative nutrition support in cancer patients: (1) Which perioperative cancer patients should receive nutrition support? (2) How can the nutrition status and requirements of these patients be optimally assessed? (3) What is the optimal route of administration (parenteral nutrition vs enteral nutrition) and composition of nutrition support in this setting? (4) When should feedings be initiated? (5) What is the role of glycemic control in these patients?</p>
</abstract>
<kwd-group>
<kwd>medical oncology</kwd>
<kwd>nutrition assessment</kwd>
<kwd>nutritional support</kwd>
<kwd>enteral nutrition</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>blood glucose</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>It is recognized that malnutrition plays an important role in surgical patients and in cancer patients. As long ago as 1936, it was noted that patients with loss of &gt;20% of their usual body weight were at 8-fold risk of dying following a surgical procedure.<sup><xref ref-type="bibr" rid="bibr1-0884533612455203">1</xref></sup> At the same time, it was observed that malnutrition and weight loss are often contributors to the death of cancer patients.<sup><xref ref-type="bibr" rid="bibr2-0884533612455203">2</xref>,<xref ref-type="bibr" rid="bibr3-0884533612455203">3</xref></sup> It was not until the 1960s and 1970s, however, with the description by Dudrick and colleagues<sup><xref ref-type="bibr" rid="bibr4-0884533612455203">4</xref>,<xref ref-type="bibr" rid="bibr5-0884533612455203">5</xref></sup> of the development and use of parenteral nutrition (PN), that it became feasible to attempt to feed perioperative cancer patients and thereby potentially mitigate the devastating consequences of malnutrition in this at-risk population. Since that time, much work has gone into defining the most appropriate role for nutrition support (NS) in perioperative cancer patients, often with ambiguous or disappointing conclusions.<sup><xref ref-type="bibr" rid="bibr6-0884533612455203">6</xref></sup> Although a consensus has gradually emerged that there is an important role for NS (both enteral and parenteral) in these patients to improve clinical outcomes, a number of specific issues concerning the use of NS continue to evolve.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref><xref ref-type="bibr" rid="bibr8-0884533612455203"/><xref ref-type="bibr" rid="bibr9-0884533612455203"/>-<xref ref-type="bibr" rid="bibr10-0884533612455203">10</xref></sup> This article reviews 5 of these issues:</p>
<list id="list1-0884533612455203" list-type="order">
<list-item><p>Which perioperative cancer patients should receive NS?</p></list-item>
<list-item><p>How can the nutrition status and requirements of these patients be optimally assessed?</p></list-item>
<list-item><p>What is the optimal route of administration (PN vs enteral nutrition [EN]) and composition of NS in this setting?</p></list-item>
<list-item><p>When should feedings be initiated?</p></list-item>
<list-item><p>What is the role of glycemic control in these patients?</p></list-item>
</list>
<p>For a more comprehensive summary of the use of NS in perioperative cancer patients, many good reviews are available.<sup><xref ref-type="bibr" rid="bibr6-0884533612455203">6</xref>,<xref ref-type="bibr" rid="bibr11-0884533612455203">11</xref></sup></p>
<sec id="section1-0884533612455203">
<title>Which Perioperative Cancer Patients Should Receive NS?</title>
<p>As noted earlier, the relationship between malnutrition and poor surgical outcomes is undeniable. Furthermore, malnutrition is prevalent in cancer patients and has an adverse impact on survival.<sup><xref ref-type="bibr" rid="bibr12-0884533612455203">12</xref></sup> On the surface, it therefore makes sense that feeding cancer patients who are undergoing or about to undergo major surgical procedures should improve surgical outcomes. However, a number of mitigating factors must be considered before accepting this conclusion. Thoughtful consideration of a classic clinical trial, the Veterans Affairs (VA) Total Parenteral Nutrition Cooperative Study Group investigation of perioperative PN, highlights many of these caveats.<sup><xref ref-type="bibr" rid="bibr13-0884533612455203">13</xref></sup> Although only approximately two-thirds of the participants in this study were cancer patients, the findings appear quite relevant to a discussion of the indications of perioperative NS in cancer patients. In this trial, 3259 potential participants potentially eligible for randomization were identified. Because the study protocol mandated that the experimental group receive preoperative PN for at least 7 days, patients were excluded if their planned operation could not be delayed, if they had a major concurrent illness that precluded administration of PN, or if it was felt that PN was “essential.” In addition, almost 40% of assessed patients were excluded from the trial because they had no evidence of malnutrition. Of the 782 patients who were ultimately eligible for randomization, 459 eventually consented and were entered into the trial. Patients were stratified according to nutrition status at the time of study entry (borderline, mildly, or severely malnourished) using a nutrition risk index formula that evaluates the serum albumin level and the ratio of current weight/usual weight. In the group receiving PN, there were 11 intravenous (IV) catheter-related complications (6%), and 20% of patients had at least 1 serum glucose measured &gt;300 mg/dL. When the incidence of complications was assessed 30 days after the initial nutrition risk stratification, 2 clear trends emerged. First, in the severely malnourished patients, the incidence of major infectious complications was equal in the control and PN groups, but the incidence of major noninfectious complications was significantly higher in the control group. Simplistically, this suggests that feeding severely malnourished patients helps to avoid surgical “healing” complications such as wound dehisence and anastomotic leak. Intuitively, one might expect PN to be most helpful in providing nutrients for the healing process and for the benefits of those nutrients to be most evident in malnourished patients. Second, feeding borderline or mildly malnourished patients was delterious; it had no effect on the incidence of healing complications, but the incidence of major infectious complications was higher in the PN group than in the control group. The results of the study may be summarized with 2 conclusions: feeding adequately nourished perioperative patients parenterally does not help and may increase the risk of infectious complications, and feeding severely malnourished patients parenterally is generally beneficial because it helps avoid complications relating to surgical healing. Numerous other studies of perioperative PN confirm these findings.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref></sup></p>
<p>Although the VA Cooperative Study investigated PN, similar trials have looked at the use of perioperative EN in cancer patients. An especially well-designed and enlightening study is that by Heslin et al.<sup><xref ref-type="bibr" rid="bibr14-0884533612455203">14</xref></sup> These investigators randomized 195 patients undergoing surgery for major upper abdominal cancers to either IV crystalloid solutions postoperatively or tube feedings through an operatively placed jejunostomy tube. The EN patients received a so-called immune-enhancing feeding formula containing supplemental arginine, RNA, and ω-3 fatty acids. The patients were not nutritionally stratified. There were no evident differences in the outcomes in the 2 groups with respect to wound or infectious complications or with respect to operative mortality. Again, one must conclude that feeding all but severely malnourished patients in the perioperative setting provides no benefits. Again, these findings are corroborated by many other studies.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref></sup> In contrast, there are ample data that administration of EN perioperatively to malnourished cancer patients, especially immune-enhancing formulas, reduces the incidence of surgical compliations (including infectious complications).<sup><xref ref-type="bibr" rid="bibr15-0884533612455203">15</xref></sup> An example of this is 2 studies by Braga and colleagues<sup><xref ref-type="bibr" rid="bibr16-0884533612455203">16</xref>,<xref ref-type="bibr" rid="bibr17-0884533612455203">17</xref></sup> that illustrate a benefit of preoperative nutrition intervention with this same formula in a population with malnutrition.</p>
<p>These data form the basis for the recommendation that perioperative NS therapy in cancer patients should be reserved for those patients who are moderately to severely malnourished or who are at risk for not receiving adequate nutrition orally for at least 7–14 days postoperatively.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref>,<xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref>,<xref ref-type="bibr" rid="bibr19-0884533612455203">19</xref></sup> Routine use of NS is not indicated in well-nourished or mildly malnourished patients who are pursuing an uncomplicated perioperative course and who are expected to eat adequately within 7–14 days.</p>
</sec>
<sec id="section2-0884533612455203">
<title>How Can the Nutrition Status and Requirements of Perioperative Cancer Patients Be Optimally Assessed?</title>
<p>It is challenging to define and measure nutrition status in cancer patients. Many traditional markers of nutrition status (serum albumin concentration, total lymphocyte count, skin test reactivity, anthropometric changes, body composition) may also be affected by the severity of the underlying cancer. Differentiation of the effects of malnutrition from the effects of the severity of illness is problematic. Several parameters have been explored as indicators of nutrition status. Hypoalbuminemia is associated with increased surgical mortality and morbidity, especially sepsis and poor healing.<sup><xref ref-type="bibr" rid="bibr13-0884533612455203">13</xref></sup> Unfortunately, the interaction between malnutrition and acute phase response proteins limits the use of nutrition indicators such as serum albumin and prealbumin levels. Weight loss, another suggested indicator, can also be unreliable in cancer patients due to fluid shifts and resultant edema seen in these patients. It has been suggested that neither serum albumin nor weight loss in isolation are specific predictors of complications,<sup><xref ref-type="bibr" rid="bibr20-0884533612455203">20</xref></sup> but they are strong predictors within multivariable models. Many formulas have been developed to predict the impact of nutrition status on morbidity and mortality in surgical patients; the predictive value of these formulas varies.<sup><xref ref-type="bibr" rid="bibr21-0884533612455203">21</xref></sup></p>
<p>Nutrition screening, a precursor step to identify those patients who should undergo a more formal nutrition assessment, facilitates the early recognition of malnutrition.<sup><xref ref-type="bibr" rid="bibr22-0884533612455203">22</xref></sup> The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) and the Academy of Nutrition and Dietetics recommend that all cancer patients undergo nutrition screening as a component of their initial evaluation.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref>,<xref ref-type="bibr" rid="bibr23-0884533612455203">23</xref>,<xref ref-type="bibr" rid="bibr24-0884533612455203">24</xref></sup> To create a clear picture of the patient’s nutrition status, objective and subjective data should be incorporated into the nutrition screening.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup> Individual objective measures, such as a single laboratory parameter or current weight, alone are not specific enough to indicate nutrition risk,<sup><xref ref-type="bibr" rid="bibr25-0884533612455203">25</xref></sup> so multiple objective measures must be combined with subjective measures related to nutrition.<sup><xref ref-type="bibr" rid="bibr23-0884533612455203">23</xref>,<xref ref-type="bibr" rid="bibr24-0884533612455203">24</xref></sup> To facilitate routine screening of all patients, nutrition screening tools should also be easy to use, cost-effective, valid, reliable, and sensitive.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup></p>
<p>Several nutrition screening tools have been used in cancer patients to identify those who are at greatest risk for developing nutrition problems. The Patient-Generated Subjective Global Assessment<sup><xref ref-type="bibr" rid="bibr26-0884533612455203">26</xref></sup> (PG-SGA, a modification of an earlier screening tool called the Subjective Global Assessment<sup><xref ref-type="bibr" rid="bibr27-0884533612455203">27</xref></sup>), the Mini Nutritional Assessment (MNA),<sup><xref ref-type="bibr" rid="bibr28-0884533612455203">28</xref></sup> the Malnutrition Screening Tool (MST),<sup><xref ref-type="bibr" rid="bibr29-0884533612455203">29</xref>,<xref ref-type="bibr" rid="bibr30-0884533612455203">30</xref></sup> the Malnutrition Universal Screening Tool (MUST),<sup><xref ref-type="bibr" rid="bibr31-0884533612455203">31</xref>,<xref ref-type="bibr" rid="bibr32-0884533612455203">32</xref></sup> and the Nutritional Risk Screening (NRS)<sup><xref ref-type="bibr" rid="bibr33-0884533612455203">33</xref></sup> are examples.</p>
<p>Nutrition screening is of little benefit if it is not followed by a formal, systematic nutrition assessment and development of a clearly outlined plan for intervention and reassessment in those patients whose screen demonstrates risk. When formulating this assessment, it is important to remember that the impact of cancer on basal energy expenditure is variable. Cancer patients may have reduced, normal, or increased energy expenditure.<sup><xref ref-type="bibr" rid="bibr34-0884533612455203">34</xref>,<xref ref-type="bibr" rid="bibr35-0884533612455203">35</xref></sup> This variability is caused by individual responses to the tumor, body composition, and tumor type and stage.<sup><xref ref-type="bibr" rid="bibr36-0884533612455203">36</xref></sup> In addition, by-products of the tumor can affect metabolism.<sup><xref ref-type="bibr" rid="bibr37-0884533612455203">37</xref></sup> Because of this variability, it is hard to predict energy requirements for cancer patients.</p>
<p>In light of these issues, it is recommended that all perioperative cancer patients undergo a formal nutrition assessment using a validated instrument. A widely used tool is the scored PG-SGA,<sup><xref ref-type="bibr" rid="bibr26-0884533612455203">26</xref></sup> which includes elements of the medical history obtained by both the clinician and the patients (weight change, dietary intake, gastrointestinal [GI] symptoms, changes in functional status, and primary diagnosis) and of the physical exam (loss of subcutaneous fat, muscle wasting, and the presence of edema and/or ascites). <xref ref-type="table" rid="table1-0884533612455203">Table 1</xref> describes the components of the PG-SGA. The PG-SGA can be used to stratify the degree of malnutrition and be used to help guide decisions concerning NS interventions.<sup><xref ref-type="bibr" rid="bibr38-0884533612455203">38</xref></sup></p>
<table-wrap id="table1-0884533612455203" position="float">
<label>Table 1.</label>
<caption><p>Components of the Patient-Generated Subjective Global Assessment<sup><xref ref-type="bibr" rid="bibr26-0884533612455203">26</xref></sup></p></caption>
<graphic alternate-form-of="table1-0884533612455203" xlink:href="10.1177_0884533612455203-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td rowspan="4">Patient completed portion</td>
<td>Weight history</td>
</tr>
<tr>
<td>Occurrence of nutrition impact symptoms</td>
</tr>
<tr>
<td>Usual vs current oral intake</td>
</tr>
<tr>
<td>Usual vs current physical activity</td>
</tr>
<tr>
<td rowspan="5">Clinician completed portion</td>
<td>Disease and its relation to nutrition requirements</td>
</tr>
<tr>
<td> Presence of cancer, AIDS, or pulmonary or cardiac cachexia; presence of decubitus, open wound, or fistula; presence of trauma; age older than 65 years</td>
</tr>
<tr>
<td>Metabolic demand</td>
</tr>
<tr>
<td> Presence of fever or use of steroids</td>
</tr>
<tr>
<td>Physical assessment</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section3-0884533612455203">
<title>What Is the Optimal Route of Administration (PN vs EN) and Composition of NS in Perioperative Cancer Patients?</title>
<p>The use of NS in cancer patients has been approached with caution in the past due to concern that provision of nutrients may stimulate tumor growth and metastasis. Murine models have indicated that PN provision in excess of energy requirements more than doubles the rate of tumor growth.<sup><xref ref-type="bibr" rid="bibr39-0884533612455203">39</xref><xref ref-type="bibr" rid="bibr40-0884533612455203"/>-<xref ref-type="bibr" rid="bibr41-0884533612455203">41</xref></sup> Some data are available in humans. A study of malnourished gastric cancer patients receiving PN indicated no increase in tumor proliferation.<sup><xref ref-type="bibr" rid="bibr42-0884533612455203">42</xref></sup> An increase in tumor cell proliferation and protein synthesis has been observed in patients with head and neck and colorectal cancer receiving PN. It is unlikely that this is of clinical significance, but it often comes up as an issue in clinical practice.<sup><xref ref-type="bibr" rid="bibr43-0884533612455203">43</xref><xref ref-type="bibr" rid="bibr44-0884533612455203"/>-<xref ref-type="bibr" rid="bibr45-0884533612455203">45</xref></sup></p>
<sec id="section4-0884533612455203">
<title>EN</title>
<p>Enteral administration of nutrients postoperatively is generally the first choice in surgical patients<sup><xref ref-type="bibr" rid="bibr46-0884533612455203">46</xref></sup> because it is theoretically more physiologic, it may be associated with fewer complications, and it is less expensive than PN.<sup><xref ref-type="bibr" rid="bibr47-0884533612455203">47</xref></sup> An early meta-analysis suggested cost benefits of EN over PN.<sup><xref ref-type="bibr" rid="bibr48-0884533612455203">48</xref></sup> Subsequent meta-analyses have confirmed this economic advantage and have also indicated a decreased risk of infection associated with EN in comparison to PN.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref>,<xref ref-type="bibr" rid="bibr49-0884533612455203">49</xref></sup> Studies also indicate decreased intestinal permeability and a lower incidence of hyperglycemia in comparison to PN.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup> EN is generally well tolerated postoperatively, with GI side effects including diarrhea and vomiting usually corrected with temporary decreases in the enteral formula infusion rate.<sup><xref ref-type="bibr" rid="bibr6-0884533612455203">6</xref></sup></p>
<p>The use of EN in surgical oncology patients has been explored in depth.<sup><xref ref-type="bibr" rid="bibr50-0884533612455203">50</xref>,<xref ref-type="bibr" rid="bibr51-0884533612455203">51</xref></sup> Use of EN is associated with improvements in nitrogen balance and sometimes associated with weight gain in cancer patients.<sup><xref ref-type="bibr" rid="bibr50-0884533612455203">50</xref></sup> PN has also been associated with improvements in nitrogen balance, and PN appears to more consistently support weight gain.<sup><xref ref-type="bibr" rid="bibr50-0884533612455203">50</xref></sup> However, this weight gain is primarily fat.<sup><xref ref-type="bibr" rid="bibr52-0884533612455203">52</xref></sup> Although it may improve patient comfort and sense of well-being, it has little impact on the physiologic effects of malnutrition.<sup><xref ref-type="bibr" rid="bibr50-0884533612455203">50</xref>,<xref ref-type="bibr" rid="bibr53-0884533612455203">53</xref></sup></p>
</sec>
<sec id="section5-0884533612455203">
<title>PN</title>
<p>Studies in the 1980s and 1990s indicated reduced morbidity and mortality with perioperative PN supplementation in cancer patients, especially those with GI malignancies.<sup><xref ref-type="bibr" rid="bibr54-0884533612455203">54</xref></sup> In retrospect, these studies had design flaws (the inclusion of heterogeneous populations, variable and likely suboptimal macronutrient provision, and inadequate sample sizes).<sup><xref ref-type="bibr" rid="bibr6-0884533612455203">6</xref></sup> More recent studies of routine (ie, not guided by nutrition risk and the results of a formal nutrition assessment) perioperative PN, primarily in GI cancer patients, indicate increased incidence of infection in patients receiving PN, with no improvement in survival.<sup><xref ref-type="bibr" rid="bibr51-0884533612455203">51</xref>,<xref ref-type="bibr" rid="bibr55-0884533612455203">55</xref>,<xref ref-type="bibr" rid="bibr56-0884533612455203">56</xref></sup> The limited data available in moderately or severely malnourished GI cancer patients also do not indicate a benefit of perioperative PN over EN but do suggest a benefit over standard isotonic fluids.<sup><xref ref-type="bibr" rid="bibr51-0884533612455203">51</xref>,<xref ref-type="bibr" rid="bibr55-0884533612455203">55</xref>,<xref ref-type="bibr" rid="bibr56-0884533612455203">56</xref></sup> The use of PN in cancer patients is not without risk, including increased infection rate, increased surgical complication rate, and increased cost.<sup><xref ref-type="bibr" rid="bibr55-0884533612455203">55</xref>,<xref ref-type="bibr" rid="bibr57-0884533612455203">57</xref><xref ref-type="bibr" rid="bibr58-0884533612455203"/>-<xref ref-type="bibr" rid="bibr59-0884533612455203">59</xref></sup></p>
</sec>
<sec id="section6-0884533612455203">
<title>Immunonutrition</title>
<p>Immunonutrition refers to the use of specific nutrients to achieve clinical outcomes. The most widely researched formula contains a combination of arginine, ω-3 fatty acids, and nucleotides. The 2009 A.S.P.E.N. guidelines for NS during adult anticancer treatment recommend the use of immune-enhancing formulas in patients undergoing major cancer operations.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref></sup> Since the publication of these guidelines, several meta-analyses have been published that confirm the benefit of perioperative use of these formulas in malnourished patients as they appear to decrease the incidence of infectious complications and anastomotic leaks, as well as reduce the length of stay.<sup><xref ref-type="bibr" rid="bibr15-0884533612455203">15</xref>,<xref ref-type="bibr" rid="bibr60-0884533612455203">60</xref><xref ref-type="bibr" rid="bibr61-0884533612455203"/>-<xref ref-type="bibr" rid="bibr62-0884533612455203">62</xref></sup></p>
<p>As previously noted, the use of perioperative NS should be limited to malnourished patients and to those patients who are unlikely to be able to meet their nutrition needs orally for at least 7–14 days. In these patients, it is recommended that therapy be started with EN if the gut is functional and there is appropriate enteral access. In this regard, it is important to consider placement of a feeding tube at the time of the primary cancer operation if the patient is at risk for nutrition-related complications.<sup><xref ref-type="bibr" rid="bibr6-0884533612455203">6</xref></sup> It seems appropriate to initiate EN with an immune-enhancing formula. In patients for whom NS is indicated but EN is not possible because of GI dysfunction or inadequate access, the use of PN is appropriate and helpful.</p>
</sec>
</sec>
<sec id="section7-0884533612455203">
<title>When Should Feedings Be Initiated?</title>
<p>The American Gastroenterological Association (2001) and A.S.P.E.N. (2009) hold similar positions on the use of PN in oncology patients.<sup><xref ref-type="bibr" rid="bibr7-0884533612455203">7</xref>,<xref ref-type="bibr" rid="bibr63-0884533612455203">63</xref></sup> The use of NS in cancer patients should generally be reserved for those circumstances when a patient is moderately or severely malnourished and in whom active therapy is planned to treat the underlying malignancy and who is unlikely to be unable to meet nutrition requirements orally for more than 7–10 days.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup> PN is appropriate in malnourished patients who are anticipated to be unable to ingest and/or absorb adequate nutrients enterally for a prolonged period of time, defined as more than 7–10 days.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup> This type of nutrition is considered aggressive due to its invasive nature. Aggressive NS such as PN should be avoided in most cases if a patient’s life expectancy is less than 40–60 days.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup> If a goal is maintenance of hydration and electrolyte balance in a patient with a life expectancy of less than 40 days, hydration therapy with IV fluids only is recommended.<sup><xref ref-type="bibr" rid="bibr18-0884533612455203">18</xref></sup></p>
<p>Historically, enteral feeding has been discouraged following GI and abdominal vascular surgical procedures. “Bowel rest” was thought to promote anastomotic healing and prevent nausea and vomiting.<sup><xref ref-type="bibr" rid="bibr64-0884533612455203">64</xref></sup> More recently, it has become clear that GI function returns rapidly postoperatively in most patients, and intraluminal nutrients promote bowel hypertrophy and anastomotic healing.<sup><xref ref-type="bibr" rid="bibr64-0884533612455203">64</xref></sup> The small intestine regains the ability to absorb nutrients quickly after surgery, even in the absence of peristalsis. Early EN in surgical patients is associated with improved wound healing, maintenance of gut function, and improved gut immune function. It is also associated with decreased length of stay in intensive care.<sup><xref ref-type="bibr" rid="bibr47-0884533612455203">47</xref>,<xref ref-type="bibr" rid="bibr64-0884533612455203">64</xref>,<xref ref-type="bibr" rid="bibr65-0884533612455203">65</xref></sup> Furthermore, early resumption of oral/enteral feeding is only occasionally associated with unwanted side effects such as nausea, vomiting, colic, and anorexia. Maintenance of nutrition status perioperatively can be facilitated by careful preoperative planning and creation of a postoperative nutrition care plan.<sup><xref ref-type="bibr" rid="bibr49-0884533612455203">49</xref></sup> Failure to consider nutrition and diet issues perioperatively can result in lost opportunities to maintain nutrition status and to avoid nutrition-related complications.</p>
<p>Although early initiation of EN in perioperative cancer patients is beneficial, a recent study clarifies the optimal timing of the initiation of PN in critically ill patients.<sup><xref ref-type="bibr" rid="bibr66-0884533612455203">66</xref></sup> Although only approximately 20% of the patients in this study had cancer, the results seem relevant to cancer patients. Only patients with moderate or severe malnutrition were eligible for inclusion in the trial. The study included both perioperative and nonsurgical patients. Patients were randomized to receive either early PN (EN supplemented by PN started on day 2 as needed to achieve the assessed caloric intake goal) or late PN with EN started on day 2 and supplemental PN started on day 7 as needed to achieve the assessed caloric intake goal. Mortality in the 2 groups was similar. However, the length of intensive care unit (ICU) stay was lower in the late initiation group, and this group also had small but significant reductions in the incidences of infectious complications, organ dysfunction, and length of hospital stay. These data suggest it is reasonable to delay the initiation of PN for at least 7 days until it is clear that it is required.</p>
<p>In summary, with proper perioperative planning and thoughtful placement of gastric and/or enteral tubes at the time of surgery, early postoperative initiation of EN in malnourished cancer patients is indicated. If energy requirements cannot be met enterally because of access complications or gut failure, it is appropriate to delay the initiation of PN for at least 7 days.</p>
</sec>
<sec id="section8-0884533612455203">
<title>What Is the Role of Glycemic Control in Perioperative Cancer Patients?</title>
<p>Hyperglycemia is frequently observed in stressed, critically ill patients and in patients receiving NS. Multiple factors contribute to this, including elevated levels of stress hormones (including corticosteroids and catecholamines), exogenous administration of glucocorticoids and catecholamines, systemic activation by inflammatory cytokines that alter intermediary metabolism and engender insulin resistance, and administration of carbohydrate-containing formulas (including EN and PN).<sup><xref ref-type="bibr" rid="bibr67-0884533612455203">67</xref></sup> No prospective randomized clinical trials have investigated the relationship between blood glucose control in perioperative surgical patients receiving NS and surgical outcomes. Nevertheless, it is reasonable to assume that the issues of blood sugar control in these patients are similar to those that have been studied in critically ill patients. Patients undergoing major operations and who are malnourished are often critically ill, and major surgery engenders many of the hormonal and cytokine changes seen in critically ill patients. Furthermore, many of the participants in randomized trials that have investigated the role of glycemic control in critically ill patients were in fact surgical patients (0%–100%). In a variety of settings (including perioperative settings), the occurrence of hyperglycemia is associated with increased morbidity and mortality, but concerns exist regarding the practicality of tight blood glucose control in critically ill patients and the dangers of iatrogenic hypoglycemia.<sup><xref ref-type="bibr" rid="bibr68-0884533612455203">68</xref></sup></p>
<p>What is the role of glycemic control in perioperative cancer patients? This can be inferred from a review of 5 major trials encompassing more than 10,000 participants conducted in critically ill patients (the proportion of these patients with cancer cannot be determined from the available publications). These trials are summarized in <xref ref-type="table" rid="table2-0884533612455203">Table 2</xref> and have been nicely reviewed by Inzucchi and Siegel.<sup><xref ref-type="bibr" rid="bibr69-0884533612455203">69</xref></sup> In these studies, blood glucose levels were monitored frequently, and IV insulin was used in the experimental groups to maintain blood sugars below approximately 110 mg/dL. In the conventional treatment groups, the blood sugar target was higher (140–200 mg/dL). In the 2 earliest studies by the van den Berghe group,<sup><xref ref-type="bibr" rid="bibr70-0884533612455203">70</xref>,<xref ref-type="bibr" rid="bibr71-0884533612455203">71</xref></sup> tight blood glucose control reduced mortality compared with less stringent control, although in the second of these 2 studies, the mortality difference was not statistically significant. Both of these studies were single-institution trials, raising the issue of whether their specific approach could be replicated elsewhere. In 3 more recent multi-institutional studies, mortality was increased in the tight glucose control groups, although the differences were only statistically significant in the Normo-glycemia in Intensive Care Evaluation–Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial.<sup><xref ref-type="bibr" rid="bibr67-0884533612455203">67</xref>,<xref ref-type="bibr" rid="bibr72-0884533612455203">72</xref>,<xref ref-type="bibr" rid="bibr73-0884533612455203">73</xref></sup> All of these trials observed a higher incidence of hyperglycemia in the stringent control groups than in the conventional therapy groups. It is possible that the van den Berghe group studies demonstrated improved mortality in the experimental groups because the glucose target in the control groups was not as stringent. The observation of an increased mortality from tight glucose control in the NICE-SUGAR study may have been due to subtle effects of hypoglycemia in intubated, sedated patients; exogenous insulin-induced dysregulation of adaptive alterations in glucose metabolism in critically ill patients; or even single-minded focus on blood sugar control to the detriment of other life-saving ICU measures. This cannot be determined at the present time.<sup><xref ref-type="bibr" rid="bibr69-0884533612455203">69</xref></sup></p>
<table-wrap id="table2-0884533612455203" position="float">
<label>Table 2.</label>
<caption><p>Randomized Trials of Glycemic Control in Critically Ill Patients</p></caption>
<graphic alternate-form-of="table2-0884533612455203" xlink:href="10.1177_0884533612455203-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th/>
<th align="center" colspan="2">Blood Glucose Target (mg/dL)<hr/></th>
<th/>
</tr>
<tr>
<th align="left">Trial Year</th>
<th align="center">ICU Type</th>
<th align="center">Tight Control</th>
<th align="center">Standard Control</th>
<th align="center">Odds Ratio (Death; &lt;1.0 Favors Tight Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2001<sup><xref ref-type="bibr" rid="bibr70-0884533612455203">70</xref></sup></td>
<td>Surgical</td>
<td>80–110</td>
<td>180–200</td>
<td>0.58<xref ref-type="table-fn" rid="table-fn2-0884533612455203">*</xref></td>
</tr>
<tr>
<td>2006<sup><xref ref-type="bibr" rid="bibr71-0884533612455203">71</xref></sup></td>
<td>Medical</td>
<td>80–110</td>
<td>180–200</td>
<td>0.94</td>
</tr>
<tr>
<td>2007<sup><xref ref-type="bibr" rid="bibr72-0884533612455203">72</xref></sup></td>
<td>Mixed</td>
<td>80–110</td>
<td>140–180</td>
<td>1.10</td>
</tr>
<tr>
<td>2008<sup><xref ref-type="bibr" rid="bibr73-0884533612455203">73</xref></sup></td>
<td>Mixed</td>
<td>80–110</td>
<td>180–200</td>
<td>NR, NS</td>
</tr>
<tr>
<td>2009<sup><xref ref-type="bibr" rid="bibr68-0884533612455203">68</xref></sup></td>
<td>Mixed</td>
<td>81–108</td>
<td>144–180</td>
<td>1.14<xref ref-type="table-fn" rid="table-fn2-0884533612455203">*</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533612455203">
<p>ICU, intensive care unit; NR, not reported; NS, death rate at 28 days not statistically different.</p>
</fn>
<fn id="table-fn2-0884533612455203">
<label>*</label>
<p>Statistically significant.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The use of NS in these studies was not well characterized, so interactions between blood glucose control and feeding cannot be determined. Interestingly, Bistrian<sup><xref ref-type="bibr" rid="bibr74-0884533612455203">74</xref></sup> has raised the question of whether stringent blood sugar control may be more problematic in patients receiving EN rather than PN because the more frequent interruptions of feeding in patients receiving EN and temporal variability in absorption may predispose these patients to hypoglycemic episodes.<sup><xref ref-type="bibr" rid="bibr74-0884533612455203">74</xref>,<xref ref-type="bibr" rid="bibr75-0884533612455203">75</xref></sup> In light of this caveat and the fact that many of these patients were not surgical patients or cancer patients, the role of stringent blood sugar control in perioperative cancer patients must be interpreted with caution. It seems prudent in these patients to target a postprandial blood sugar in the 140- to 180-mg/dL range to attain at least some of the benefits of more stringent glucose control but without risking the possible increase in mortality that may result from overly tight control.<sup><xref ref-type="bibr" rid="bibr76-0884533612455203">76</xref>,<xref ref-type="bibr" rid="bibr77-0884533612455203">77</xref></sup></p>
</sec>
<sec id="section9-0884533612455203">
<title>Summary</title>
<p>The answers to the questions posed at the beginning of this article may be summarized as follows:</p>
<list id="list2-0884533612455203" list-type="order">
<list-item><p><italic>Which perioperative cancer patients should receive NS?</italic> The use of perioperative NS in cancer patients should be reserved for those patients who are moderately or severely malnourished and who are anticipated to be unable to meet their nutrition needs for at least 7–14 days.</p></list-item>
<list-item><p><italic>How can the nutrition status and requirements of these patients be optimally assessed?</italic> All perioperative cancer patients should undergo a formal nutrition assessment using a validated instrument. A widely used, validated tool is the scored PG-SGA.<sup><xref ref-type="bibr" rid="bibr26-0884533612455203">26</xref></sup></p></list-item>
<list-item><p><italic>What is the optimal route of administration (PN vs EN) and composition of NS in this setting?</italic> EN is preferred in perioperative cancer patients, but PN may be used if enteral access cannot be attained or in the presence of gut failure. In these patients, when EN is feasible, use of an immune-enhancing formula is appropriate.</p></list-item>
<list-item><p><italic>When should feedings be initiated?</italic> Early postoperative initiation of EN in malnourished cancer patients is indicated. If energy requirements cannot be met enterally because of access complications or gut failure, it is appropriate to delay the initiation of PN for at least 7 days.</p></list-item>
<list-item><p><italic>What is the role of glycemic control in these patients?</italic> It is prudent to target a blood sugar in the 140- to 180-mg/dL range to attain at least some of the benefits of more stringent glucose control but without risking the possible increase in mortality that may result from overly tight control.</p></list-item>
</list>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosure: none declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533612455203">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Studley</surname><given-names>H</given-names></name>
</person-group>. <article-title>Percentage of weight loss</article-title>. <source>JAMA</source>. <year>1936</year>;<volume>106</volume>:<fpage>458</fpage>-<lpage>460</lpage>.</citation>
</ref>
<ref id="bibr2-0884533612455203">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Warren</surname><given-names>S</given-names></name>
</person-group>. <article-title>The immediate cause of death in cancer</article-title>. <source>Am J Med Sci</source>. <year>1932</year>;<volume>185</volume>:<fpage>610</fpage>-<lpage>615</lpage>.</citation>
</ref>
<ref id="bibr3-0884533612455203">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inagaki</surname><given-names>J</given-names></name>
<name><surname>Rodriguez</surname><given-names>V</given-names></name>
<name><surname>Bodey</surname><given-names>GP</given-names></name>
</person-group>. <article-title>Proceedings: causes of death in cancer patients</article-title>. <source>Cancer</source>. <year>1974</year>;<volume>33</volume>(<issue>2</issue>):<fpage>568</fpage>-<lpage>573</lpage>.</citation>
</ref>
<ref id="bibr4-0884533612455203">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dudrick</surname><given-names>SJ</given-names></name>
<name><surname>Wilmore</surname><given-names>DW</given-names></name>
<name><surname>Vars</surname><given-names>HM</given-names></name>
<name><surname>Rhoads</surname><given-names>JE</given-names></name>
</person-group>. <article-title>Long-term total parenteral nutrition with growth, development, and positive nitrogen balance</article-title>. <source>Surgery</source>. <year>1968</year>;<volume>64</volume>(<issue>1</issue>):<fpage>134</fpage>-<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr5-0884533612455203">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Copeland</surname><given-names>EM</given-names></name>
<name><surname>Macfayden</surname><given-names>BV</given-names><suffix>Jr</suffix></name>
<name><surname>Dudrick</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Intravenous hyperalimentation in cancer patients</article-title>. <source>J Surg Res</source>. <year>1974</year>;<volume>16</volume>(<issue>3</issue>):<fpage>241</fpage>-<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr6-0884533612455203">
<label>6.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>D</given-names></name>
<name><surname>Huhmann</surname><given-names>M</given-names></name>
</person-group>. <article-title>Nutritional care of cancer patients</article-title>. In: <person-group person-group-type="editor">
<name><surname>Norton</surname><given-names>JA</given-names></name>
<name><surname>Bollinger</surname><given-names>RA</given-names></name>
<name><surname>Chang</surname><given-names>AE</given-names></name>
<etal/>
</person-group> eds. <source>Surgery: Basic Science and Clinical Evidence</source>. <edition>2nd ed.</edition> <publisher-loc>New York</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr7-0884533612455203">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>DA</given-names></name>
<name><surname>Huhmann</surname><given-names>MB</given-names></name>
</person-group>. <article-title>A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2009</year>;<volume>33</volume>(<issue>5</issue>):<fpage>472</fpage>-<lpage>500</lpage>.</citation>
</ref>
<ref id="bibr8-0884533612455203">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arends</surname><given-names>J</given-names></name>
<name><surname>Bodoky</surname><given-names>G</given-names></name>
<name><surname>Bozzetti</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>ESPEN guidelines on enteral nutrition: non-surgical oncology</article-title>. <source>Clin Nutr</source>. <year>2006</year>;<volume>25</volume>(<issue>2</issue>):<fpage>245</fpage>-<lpage>259</lpage>.</citation>
</ref>
<ref id="bibr9-0884533612455203">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bozzetti</surname><given-names>F</given-names></name>
<name><surname>Arends</surname><given-names>J</given-names></name>
<name><surname>Lundholm</surname><given-names>K</given-names></name>
<name><surname>Micklewright</surname><given-names>A</given-names></name>
<name><surname>Zurcher</surname><given-names>G</given-names></name>
<name><surname>Muscaritoli</surname><given-names>M</given-names></name>
</person-group>. <article-title>ESPEN guidelines on parenteral nutrition: non-surgical oncology</article-title>. <source>Clin Nutr</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>445</fpage>-<lpage>454</lpage>.</citation>
</ref>
<ref id="bibr10-0884533612455203">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braga</surname><given-names>M</given-names></name>
<name><surname>Ljungqvist</surname><given-names>O</given-names></name>
<name><surname>Soeters</surname><given-names>P</given-names></name>
<name><surname>Fearon</surname><given-names>K</given-names></name>
<name><surname>Weimann</surname><given-names>A</given-names></name>
<name><surname>Bozzetti</surname><given-names>F</given-names></name>
</person-group>. <article-title>ESPEN guidelines on parenteral nutrition: surgery</article-title>. <source>Clin Nutr</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>378</fpage>-<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr11-0884533612455203">
<label>11.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>August</surname><given-names>D</given-names></name>
<name><surname>Huhmann</surname><given-names>MB</given-names></name>
</person-group>. <article-title>Nutrition support of the cancer patient</article-title>. In: <person-group person-group-type="editor">
<name><surname>Ross</surname><given-names>A</given-names></name>
<name><surname>Caballero</surname><given-names>B</given-names></name>
<name><surname>Cousins</surname><given-names>R</given-names></name>
<name><surname>Tucker</surname><given-names>K</given-names></name>
<name><surname>Ziegler</surname><given-names>T</given-names></name>
</person-group> eds. <source>Modern Nutrition in Health and Disease</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>; <comment>in press</comment>.</citation>
</ref>
<ref id="bibr12-0884533612455203">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dewys</surname><given-names>WD</given-names></name>
<name><surname>Begg</surname><given-names>C</given-names></name>
<name><surname>Lavin</surname><given-names>PT</given-names></name>
<etal/>
</person-group>. <article-title>Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group</article-title>. <source>Am J Med</source>. <year>1980</year>;<volume>69</volume>(<issue>4</issue>):<fpage>491</fpage>-<lpage>497</lpage>.</citation>
</ref>
<ref id="bibr13-0884533612455203">
<label>13.</label>
<citation citation-type="journal">
<collab>Perioperative total parenteral nutrition in surgical patients</collab>. <article-title>The Veterans Affairs Total Parenteral Nutrition Cooperative Study Group</article-title>. <source>N Engl J Med</source>. <year>1991</year>;<volume>325</volume>(<issue>8</issue>):<fpage>525</fpage>-<lpage>532</lpage>.</citation>
</ref>
<ref id="bibr14-0884533612455203">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heslin</surname><given-names>MJ</given-names></name>
<name><surname>Latkany</surname><given-names>L</given-names></name>
<name><surname>Leung</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>A prospective, randomized trial of early enteral feeding after resection of upper gastrointestinal malignancy</article-title>. <source>Ann Surg</source>. <year>1997</year>;<volume>226</volume>(<issue>4</issue>):<fpage>567</fpage>-<lpage>577</lpage>; <comment>discussion 577-580</comment>.</citation>
</ref>
<ref id="bibr15-0884533612455203">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marik</surname><given-names>PE</given-names></name>
<name><surname>Zaloga</surname><given-names>GP</given-names></name>
</person-group>. <article-title>Immunonutrition in high-risk surgical patients: a systematic review and analysis of the literature</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2010</year>;<volume>34</volume>(<issue>4</issue>):<fpage>378</fpage>-<lpage>386</lpage>.</citation>
</ref>
<ref id="bibr16-0884533612455203">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braga</surname><given-names>M</given-names></name>
<name><surname>Gianotti</surname><given-names>L</given-names></name>
<name><surname>Vignali</surname><given-names>A</given-names></name>
<name><surname>Carlo</surname><given-names>VD</given-names></name>
</person-group>. <article-title>Preoperative oral arginine and n-3 fatty acid supplementation improves the immunometabolic host response and outcome after colorectal resection for cancer</article-title>. <source>Surgery</source>. <year>2002</year>; <volume>132</volume>(<issue>5</issue>):<fpage>805</fpage>-<lpage>814</lpage>.</citation>
</ref>
<ref id="bibr17-0884533612455203">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gianotti</surname><given-names>L</given-names></name>
<name><surname>Braga</surname><given-names>M</given-names></name>
<name><surname>Nespoli</surname><given-names>L</given-names></name>
<name><surname>Radaelli</surname><given-names>G</given-names></name>
<name><surname>Beneduce</surname><given-names>A</given-names></name>
<name><surname>Di Carlo</surname><given-names>V</given-names></name>
</person-group>. <article-title>A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer</article-title>. <source>Gastroenterology</source>. <year>2002</year>;<volume>122</volume>(<issue>7</issue>):<fpage>1763</fpage>-<lpage>1770</lpage>.</citation>
</ref>
<ref id="bibr18-0884533612455203">
<label>18.</label>
<citation citation-type="journal">
<collab>American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.)</collab> <article-title>Board of Directors. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2002</year>; <volume>26</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>1SA</fpage>-<lpage>138SA</lpage>.</citation>
</ref>
<ref id="bibr19-0884533612455203">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
</person-group>. <article-title>Nutrition support in critical illness—bridging the evidence gap</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>562</fpage>-<lpage>564</lpage>.</citation>
</ref>
<ref id="bibr20-0884533612455203">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jensen</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Inflammation as the key interface of the medical and nutrition universes: a provocative examination of the future of clinical nutrition and medicine</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2006</year>;<volume>30</volume>(<issue>5</issue>):<fpage>453</fpage>-<lpage>463</lpage>.</citation>
</ref>
<ref id="bibr21-0884533612455203">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hirsch</surname><given-names>S</given-names></name>
<name><surname>de Obaldia</surname><given-names>N</given-names></name>
<name><surname>Petermann</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Nutritional status of surgical patients and the relationship of nutrition to postoperative outcome</article-title>. <source>J Am Coll Nutr</source>. <year>1992</year>;<volume>11</volume>(<issue>1</issue>):<fpage>21</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr22-0884533612455203">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lacey</surname><given-names>K</given-names></name>
<name><surname>Pritchett</surname><given-names>E</given-names></name>
</person-group>. <article-title>Nutrition care process and model: ADA adopts road map to quality care and outcomes management</article-title>. <source>J Am Diet Assoc</source>. <year>2003</year>;<volume>103</volume>(<issue>8</issue>):<fpage>1061</fpage>-<lpage>1072</lpage>.</citation>
</ref>
<ref id="bibr23-0884533612455203">
<label>23.</label>
<citation citation-type="journal">
<collab>Council on Practice (COP) Quality Management Committee</collab>. <article-title>Identifying patients at risk: ADA’s definitions for nutrition screening and nutrition assessment</article-title>. <source>J Am Diet Assoc</source>. <year>1994</year>;<volume>94</volume>(<issue>8</issue>):<fpage>838</fpage>-<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr24-0884533612455203">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mueller</surname><given-names>C</given-names></name>
<name><surname>Compher</surname><given-names>C</given-names></name>
<name><surname>Druyan</surname><given-names>M</given-names></name>
</person-group>; <collab>American Society for Parenteral and Enteral Nutrition Board of Directors</collab>. <article-title>Nutrition screening, assessment, and intervention in adults</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>(<issue>1</issue>):<fpage>16</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr25-0884533612455203">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sarhill</surname><given-names>N</given-names></name>
<name><surname>Mahmoud</surname><given-names>F</given-names></name>
<name><surname>Walsh</surname><given-names>D</given-names></name><etal/>
</person-group>. <article-title>Evaluation of nutritional status in advanced metastatic cancer</article-title>. <source>Support Care Cancer</source>. <year>2003</year>;<volume>11</volume>(<issue>10</issue>):<fpage>652</fpage>-<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr26-0884533612455203">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ottery</surname><given-names>FD</given-names></name>
</person-group>. <article-title>Definition of standardized nutritional assessment and interventional pathways in oncology</article-title>. <source>Nutrition</source>. <year>1996</year>;<volume>12</volume>(<issue>1</issue>)(<supplement>suppl</supplement>):<fpage>S15</fpage>-<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr27-0884533612455203">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Detsky</surname><given-names>AS</given-names></name>
<name><surname>McLaughlin</surname><given-names>JR</given-names></name>
<name><surname>Baker</surname><given-names>JP</given-names></name><etal/>
</person-group>. <article-title>What is subjective global assessment of nutritional status?</article-title> <source>JPEN J Parenter Enteral Nutr</source>. <year>1987</year>; <volume>11</volume>(<issue>1</issue>):<fpage>8</fpage>-<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr28-0884533612455203">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guigoz</surname><given-names>Y</given-names></name>
<name><surname>Vellas</surname><given-names>B</given-names></name>
<name><surname>Garry</surname><given-names>PJ</given-names></name>
</person-group>. <article-title>Assessing the nutritional status of the elderly: the Mini Nutritional Assessment as part of the geriatric evaluation</article-title>. <source>Nutr Rev</source>. <year>1996</year>;<volume>54</volume>(<issue>1, pt 2</issue>):<fpage>S59</fpage>-<lpage>S65</lpage>.</citation>
</ref>
<ref id="bibr29-0884533612455203">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>M</given-names></name>
<name><surname>Capra</surname><given-names>S</given-names></name>
<name><surname>Bauer</surname><given-names>J</given-names></name>
<name><surname>Banks</surname><given-names>M</given-names></name>
</person-group>. <article-title>Development of a valid and reliable malnutrition screening tool for adult acute hospital patients</article-title>. <source>Nutrition</source>. <year>1999</year>;<volume>15</volume>(<issue>6</issue>):<fpage>458</fpage>-<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr30-0884533612455203">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferguson</surname><given-names>ML</given-names></name>
<name><surname>Bauer</surname><given-names>J</given-names></name>
<name><surname>Gallagher</surname><given-names>B</given-names></name>
<name><surname>Capra</surname><given-names>S</given-names></name>
<name><surname>Christie</surname><given-names>DR</given-names></name>
<name><surname>Mason</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Validation of a malnutrition screening tool for patients receiving radiotherapy</article-title>. <source>Australas Radiol</source>. <year>1999</year>;<volume>43</volume>(<issue>3</issue>):<fpage>325</fpage>-<lpage>327</lpage>.</citation>
</ref>
<ref id="bibr31-0884533612455203">
<label>31.</label>
<citation citation-type="journal">
<collab>Malnutrition Advisory Group</collab>. <article-title>A consistent and reliable tool for malnutrition screening</article-title>. <source>Nurs Times</source>. <year>2003</year>;<volume>99</volume>(<issue>46</issue>):<fpage>26</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr32-0884533612455203">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>J</given-names></name>
<name><surname>Capra</surname><given-names>S</given-names></name>
</person-group>. <article-title>Comparison of a malnutrition screening tool with subjective global assessment in hospitalised patients with cancer—sensitivity and specificity</article-title>. <source>Asia Pac J Clin Nutr</source>. <year>2003</year>;<volume>12</volume>(<issue>3</issue>):<fpage>257</fpage>-<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr33-0884533612455203">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kondrup</surname><given-names>J</given-names></name>
<name><surname>Rasmussen</surname><given-names>HH</given-names></name>
<name><surname>Hamberg</surname><given-names>O</given-names></name>
<name><surname>Stanga</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials</article-title>. <source>Clin Nutr</source>. <year>2003</year>;<volume>22</volume>(<issue>3</issue>):<fpage>321</fpage>-<lpage>336</lpage>.</citation>
</ref>
<ref id="bibr34-0884533612455203">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tisdale</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Pathogenesis of cancer cachexia</article-title>. <source>J Support Oncol</source>. <year>2003</year>; <volume>1</volume>(<issue>3</issue>):<fpage>159</fpage>-<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr35-0884533612455203">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barber</surname><given-names>M</given-names></name>
</person-group>. <article-title>The pathophysiology and treatment of cancer cachexia</article-title>. <source>Nutr Clin Pract</source>. <year>2002</year>;<volume>17</volume>(<issue>4</issue>):<fpage>203</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr36-0884533612455203">
<label>36.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>C</given-names></name>
</person-group>. <article-title>Calorie, protein, fluid and micronutrient requirements</article-title>. In: <person-group person-group-type="editor">
<name><surname>McCallum</surname><given-names>P</given-names></name>
<name><surname>Polisena</surname><given-names>C</given-names></name>
</person-group>, eds. <source>The Clinical Guide to Oncology Nutrition</source>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>American Dietetic Association</publisher-name>; <volume>2000</volume>:<fpage>45</fpage>-<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr37-0884533612455203">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tisdale</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Tumor-host interactions</article-title>. <source>J Cell Biochem</source>. <year>2004</year>;<volume>93</volume>(<issue>5</issue>):<fpage>871</fpage>-<lpage>877</lpage>.</citation>
</ref>
<ref id="bibr38-0884533612455203">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>J</given-names></name>
<name><surname>Capra</surname><given-names>S</given-names></name>
<name><surname>Ferguson</surname><given-names>M</given-names></name>
</person-group>. <article-title>Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer</article-title>. <source>Eur J Clin Nutr</source>. <year>2002</year>;<volume>56</volume>(<issue>8</issue>):<fpage>779</fpage>-<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr39-0884533612455203">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Popp</surname><given-names>MB</given-names></name>
<name><surname>Wagner</surname><given-names>SC</given-names></name>
<name><surname>Brito</surname><given-names>OJ</given-names></name>
</person-group>. <article-title>Host and tumor responses to increasing levels of intravenous nutritional support</article-title>. <source>Surgery</source>. <year>1983</year>;<volume>94</volume>(<issue>2</issue>):<fpage>300</fpage>-<lpage>308</lpage>.</citation>
</ref>
<ref id="bibr40-0884533612455203">
<label>40.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Daly</surname><given-names>J</given-names></name>
<name><surname>Thorn</surname><given-names>A</given-names></name>
</person-group>. <article-title>Neoplastic diseases</article-title>. In: <person-group person-group-type="editor">
<name><surname>Kinney</surname><given-names>J</given-names></name>
<name><surname>Jeejeebhoy</surname><given-names>K</given-names></name>
<name><surname>Hill</surname><given-names>G</given-names></name>
<name><surname>Owen</surname><given-names>O</given-names></name>
</person-group>, eds. <source>Nutrition and Metabolism in Patient Care</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>Saunders</publisher-name>; <volume>1988</volume>:<fpage>567</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr41-0884533612455203">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Torosian</surname><given-names>MH</given-names></name>
</person-group>. <article-title>Stimulation of tumor growth by nutrition support</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1992</year>;<volume>16</volume>(<issue>6</issue>)(<supplement>suppl</supplement>):<fpage>72S</fpage>-<lpage>75S</lpage>.</citation>
</ref>
<ref id="bibr42-0884533612455203">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pacelli</surname><given-names>F</given-names></name>
<name><surname>Bossola</surname><given-names>M</given-names></name>
<name><surname>Teodori</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Parenteral nutrition does not stimulate tumor proliferation in malnourished gastric cancer patients</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2007</year>;<volume>31</volume>(<issue>6</issue>):<fpage>451</fpage>-<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr43-0884533612455203">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baron</surname><given-names>PL</given-names></name>
<name><surname>Lawrence</surname><given-names>W</given-names><suffix>Jr</suffix></name>
<name><surname>Chan</surname><given-names>WM</given-names></name>
<name><surname>White</surname><given-names>FK</given-names></name>
<name><surname>Banks</surname><given-names>WL</given-names><suffix>Jr</suffix></name>
</person-group>. <article-title>Effects of parenteral nutrition on cell cycle kinetics of head and neck cancer</article-title>. <source>Arch Surg</source>. <year>1986</year>;<volume>121</volume>(<issue>11</issue>):<fpage>1282</fpage>-<lpage>1286</lpage>.</citation>
</ref>
<ref id="bibr44-0884533612455203">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Frank</surname><given-names>JL</given-names></name>
<name><surname>Lawrence</surname><given-names>W</given-names><suffix>Jr</suffix></name>
<name><surname>Banks</surname><given-names>WL</given-names><suffix>Jr</suffix></name>
<name><surname>McKinnon</surname><given-names>JG</given-names></name>
<name><surname>Chan</surname><given-names>WM</given-names></name>
<name><surname>Collins</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Modulation of cell cycle kinetics in human cancer with total parenteral nutrition</article-title>. <source>Cancer</source>. <year>1992</year>;<volume>69</volume>(<issue>7</issue>):<fpage>1858</fpage>-<lpage>1864</lpage>.</citation>
</ref>
<ref id="bibr45-0884533612455203">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heys</surname><given-names>SD</given-names></name>
<name><surname>Park</surname><given-names>KG</given-names></name>
<name><surname>McNurlan</surname><given-names>MA</given-names></name><etal/>
</person-group>. <article-title>Stimulation of protein synthesis in human tumours by parenteral nutrition: evidence for modulation of tumour growth</article-title>. <source>Br J Surg</source>. <year>1991</year>;<volume>78</volume>(<issue>4</issue>):<fpage>483</fpage>-<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr46-0884533612455203">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huckleberry</surname><given-names>Y</given-names></name>
</person-group>. <article-title>Nutritional support and the surgical patient</article-title>. <source>Am J Health Syst Pharm</source>. <year>2004</year>;<volume>61</volume>(<issue>7</issue>):<fpage>671</fpage>-<lpage>682</lpage>; <comment>quiz 683-684</comment>.</citation>
</ref>
<ref id="bibr47-0884533612455203">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fearon</surname><given-names>KC</given-names></name>
<name><surname>Luff</surname><given-names>R</given-names></name>
</person-group>. <article-title>The nutritional management of surgical patients: enhanced recovery after surgery</article-title>. <source>Proc Nutr Soc</source>. <year>2003</year>;<volume>62</volume>(<issue>4</issue>):<fpage>807</fpage>-<lpage>811</lpage>.</citation>
</ref>
<ref id="bibr48-0884533612455203">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lipman</surname><given-names>TO</given-names></name>
</person-group>. <article-title>Grains or veins: is enteral nutrition really better than parenteral nutrition? A look at the evidence</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1998</year>; <volume>22</volume>(<issue>3</issue>):<fpage>167</fpage>-<lpage>182</lpage>.</citation>
</ref>
<ref id="bibr49-0884533612455203">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braunschweig</surname><given-names>CL</given-names></name>
<name><surname>Levy</surname><given-names>P</given-names></name>
<name><surname>Sheean</surname><given-names>PM</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
</person-group>. <article-title>Enteral compared with parenteral nutrition: a meta-analysis</article-title>. <source>Am J Clin Nutr</source>. <year>2001</year>;<volume>74</volume>(<issue>4</issue>):<fpage>534</fpage>-<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr50-0884533612455203">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bozzetti</surname><given-names>F</given-names></name>
</person-group>. <article-title>Rationale and indications for preoperative feeding of malnourished surgical cancer patients</article-title>. <source>Nutrition</source>. <year>2002</year>;<volume>18</volume>(<issue>11-12</issue>):<fpage>953</fpage>-<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr51-0884533612455203">
<label>51.</label>
<citation citation-type="journal">
<collab>NHS Center for Reviews and Dissemination</collab>. <article-title>Nutrition support in patients with cancer</article-title>. <source>Database Abstracts Rev Effectiveness</source>. <year>2004</year>;<fpage>2</fpage>.</citation>
</ref>
<ref id="bibr52-0884533612455203">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shike</surname><given-names>M</given-names></name>
<name><surname>Russel</surname><given-names>DM</given-names></name>
<name><surname>Detsky</surname><given-names>AS</given-names></name><etal/>
</person-group>. <article-title>Changes in body composition in patients with small-cell lung cancer: the effect of total parenteral nutrition as an adjunct to chemotherapy</article-title>. <source>Ann Intern Med</source>. <year>1984</year>;<volume>101</volume>(<issue>3</issue>):<fpage>303</fpage>-<lpage>309</lpage>.</citation>
</ref>
<ref id="bibr53-0884533612455203">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyltander</surname><given-names>A</given-names></name>
<name><surname>Drott</surname><given-names>C</given-names></name>
<name><surname>Unsgaard</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>The effect on body composition and exercise performance of home parenteral nutrition when given as adjunct to chemotherapy of testicular carcinoma</article-title>. <source>Eur J Clin Invest</source>. <year>1991</year>;<volume>21</volume>(<issue>4</issue>):<fpage>413</fpage>-<lpage>420</lpage>.</citation>
</ref>
<ref id="bibr54-0884533612455203">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Muller</surname><given-names>JM</given-names></name>
<name><surname>Keller</surname><given-names>HW</given-names></name>
<name><surname>Brenner</surname><given-names>U</given-names></name>
<name><surname>Walter</surname><given-names>M</given-names></name>
<name><surname>Holzmuller</surname><given-names>W</given-names></name>
</person-group>. <article-title>Indications and effects of preoperative parenteral nutrition</article-title>. <source>World J Surg</source>. <year>1986</year>;<volume>10</volume>(<issue>1</issue>):<fpage>53</fpage>-<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr55-0884533612455203">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bozzetti</surname><given-names>F</given-names></name>
<name><surname>Braga</surname><given-names>M</given-names></name>
<name><surname>Gianotti</surname><given-names>L</given-names></name>
<name><surname>Gavazzi</surname><given-names>C</given-names></name>
<name><surname>Mariani</surname><given-names>L</given-names></name>
</person-group>. <article-title>Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial</article-title>. <source>Lancet</source>. <year>2001</year>;<volume>358</volume>(<issue>9292</issue>):<fpage>1487</fpage>-<lpage>1492</lpage>.</citation>
</ref>
<ref id="bibr56-0884533612455203">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koretz</surname><given-names>RL</given-names></name>
<name><surname>Lipman</surname><given-names>TO</given-names></name>
<name><surname>Klein</surname><given-names>S</given-names></name>
</person-group>. <article-title>AGA technical review on parenteral nutrition</article-title>. <source>Gastroenterology</source>. <year>2001</year>;<volume>121</volume>(<issue>4</issue>):<fpage>970</fpage>-<lpage>1001</lpage>.</citation>
</ref>
<ref id="bibr57-0884533612455203">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papapietro</surname><given-names>K</given-names></name>
<name><surname>Diaz</surname><given-names>E</given-names></name>
<name><surname>Csendes</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Early enteral nutrition in cancer patients subjected to a total gastrectomy [in Spanish]</article-title>. <source>Rev Med Chil</source>. <year>2002</year>;<volume>130</volume>(<issue>10</issue>):<fpage>1125</fpage>-<lpage>1130</lpage>.</citation>
</ref>
<ref id="bibr58-0884533612455203">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braga</surname><given-names>M</given-names></name>
<name><surname>Gianotti</surname><given-names>L</given-names></name>
<name><surname>Gentilini</surname><given-names>O</given-names></name>
<name><surname>Parisi</surname><given-names>V</given-names></name>
<name><surname>Salis</surname><given-names>C</given-names></name>
<name><surname>Di Carlo</surname><given-names>V</given-names></name>
</person-group>. <article-title>Early postoperative enteral nutrition improves gut oxygenation and reduces costs compared with total parenteral nutrition</article-title>. <source>Crit Care Med</source>. <year>2001</year>;<volume>29</volume>(<issue>2</issue>):<fpage>242</fpage>-<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr59-0884533612455203">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aiko</surname><given-names>S</given-names></name>
<name><surname>Yoshizumi</surname><given-names>Y</given-names></name>
<name><surname>Sugiura</surname><given-names>Y</given-names></name><etal/>
</person-group>. <article-title>Beneficial effects of immediate enteral nutrition after esophageal cancer surgery</article-title>. <source>Surg Today</source>. <year>2001</year>;<volume>31</volume>(<issue>11</issue>):<fpage>971</fpage>-<lpage>978</lpage>.</citation>
</ref>
<ref id="bibr60-0884533612455203">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drover</surname><given-names>JW</given-names></name>
<name><surname>Dhaliwal</surname><given-names>R</given-names></name>
<name><surname>Weitzel</surname><given-names>L</given-names></name>
<name><surname>Wischmeyer</surname><given-names>PE</given-names></name>
<name><surname>Ochoa</surname><given-names>JB</given-names></name>
<name><surname>Heyland</surname><given-names>DK</given-names></name>
</person-group>. <article-title>Perioperative use of arginine-supplemented diets: a systematic review of the evidence</article-title>. <source>J Am Coll Surg</source>. <year>2011</year>;<volume>212</volume>(<issue>3</issue>):<fpage>385</fpage>-<lpage>399</lpage>, <fpage>399 e381</fpage>.</citation>
</ref>
<ref id="bibr61-0884533612455203">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Waitzberg</surname><given-names>DL</given-names></name>
<name><surname>Saito</surname><given-names>H</given-names></name>
<name><surname>Plank</surname><given-names>LD</given-names></name><etal/>
</person-group>. <article-title>Postsurgical infections are reduced with specialized nutrition support</article-title>. <source>World J Surg</source>. <year>2006</year>;<volume>30</volume>(<issue>8</issue>):<fpage>1592</fpage>-<lpage>1604</lpage>.</citation>
</ref>
<ref id="bibr62-0884533612455203">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cerantola</surname><given-names>Y</given-names></name>
<name><surname>Hubner</surname><given-names>M</given-names></name>
<name><surname>Grass</surname><given-names>F</given-names></name>
<name><surname>Demartines</surname><given-names>N</given-names></name>
<name><surname>Schafer</surname><given-names>M</given-names></name>
</person-group>. <article-title>Immunonutrition in gastrointestinal surgery</article-title>. <source>Br J Surg</source>. <year>2011</year>;<volume>98</volume>(<issue>1</issue>):<fpage>37</fpage>-<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr63-0884533612455203">
<label>63.</label>
<citation citation-type="journal">
<collab>American Gastroenterological Association medical position statement: parenteral nutrition</collab>. <source>Gastroenterology</source>. <year>2001</year>;<volume>121</volume>(<issue>4</issue>):<fpage>966</fpage>-<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr64-0884533612455203">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gabor</surname><given-names>S</given-names></name>
<name><surname>Renner</surname><given-names>H</given-names></name>
<name><surname>Matzi</surname><given-names>V</given-names></name><etal/>
</person-group>. <article-title>Early enteral feeding compared with parenteral nutrition after oesophageal or oesophagogastric resection and reconstruction</article-title>. <source>Br J Nutr</source>. <year>2005</year>;<volume>93</volume>(<issue>4</issue>):<fpage>509</fpage>-<lpage>513</lpage>.</citation>
</ref>
<ref id="bibr65-0884533612455203">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersen</surname><given-names>HK</given-names></name>
<name><surname>Lewis</surname><given-names>SJ</given-names></name>
<name><surname>Thomas</surname><given-names>S</given-names></name>
</person-group>. <article-title>Early enteral nutrition within 24h of colorectal surgery versus later commencement of feeding for postoperative complications</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2006</year>;(<issue>4</issue>): <comment>CD004080</comment>.</citation>
</ref>
<ref id="bibr66-0884533612455203">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Casaer</surname><given-names>M</given-names></name>
<name><surname>Mesotten</surname><given-names>D</given-names></name>
<name><surname>Hermans</surname><given-names>G</given-names></name><etal/>
</person-group>. <article-title>Early versus late parenteral nutrition in critically ill adult patients</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>506</fpage>-<lpage>517</lpage>.</citation>
</ref>
<ref id="bibr67-0884533612455203">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kavanagh</surname><given-names>BP</given-names></name>
<name><surname>McCowen</surname><given-names>KC</given-names></name>
</person-group>. <article-title>Clinical practice: glycemic control in the ICU</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>(<issue>26</issue>):<fpage>2540</fpage>-<lpage>2546</lpage>.</citation>
</ref>
<ref id="bibr68-0884533612455203">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Finfer</surname><given-names>S</given-names></name>
<name><surname>Chittock</surname><given-names>DR</given-names></name>
<name><surname>Su</surname><given-names>SY</given-names></name><etal/>
</person-group>. <article-title>Intensive versus conventional glucose control in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>13</issue>):<fpage>1283</fpage>-<lpage>1297</lpage>.</citation>
</ref>
<ref id="bibr69-0884533612455203">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Inzucchi</surname><given-names>SE</given-names></name>
<name><surname>Siegel</surname><given-names>MD</given-names></name>
</person-group>. <article-title>Glucose control in the ICU—how tight is too tight?</article-title> <source>N Engl J Med</source>. <year>2009</year>;<volume>360</volume>(<issue>13</issue>):<fpage>1346</fpage>-<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr70-0884533612455203">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van den Berghe</surname><given-names>G</given-names></name>
<name><surname>Wouters</surname><given-names>P</given-names></name>
<name><surname>Weekers</surname><given-names>F</given-names></name>
<etal/>
</person-group>. <article-title>Intensive insulin therapy in critically ill patients</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>19</issue>):<fpage>1359</fpage>-<lpage>1367</lpage>.</citation>
</ref>
<ref id="bibr71-0884533612455203">
<label>71.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van den Berghe</surname><given-names>G</given-names></name>
<name><surname>Wilmer</surname><given-names>A</given-names></name>
<name><surname>Hermans</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Intensive insulin therapy in the medical ICU</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>354</volume>(<issue>5</issue>):<fpage>449</fpage>-<lpage>461</lpage>.</citation>
</ref>
<ref id="bibr72-0884533612455203">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Devos</surname><given-names>P</given-names></name>
<name><surname>Preiser</surname><given-names>J</given-names></name>
<name><surname>Melot</surname><given-names>C</given-names></name>
</person-group>. <article-title>Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the Glucontrol study</article-title>. <source>Intensive Care Med</source>. <year>2007</year>;<volume>33</volume> (<issue>suppl 2</issue>):<fpage>S189</fpage>.</citation>
</ref>
<ref id="bibr73-0884533612455203">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brunkhorst</surname><given-names>FM</given-names></name>
<name><surname>Engel</surname><given-names>C</given-names></name>
<name><surname>Bloos</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Intensive insulin therapy and pentastarch resuscitation in severe sepsis</article-title>. <source>N Engl J Med</source>. <year>2008</year>;<volume>358</volume>(<issue>2</issue>):<fpage>125</fpage>-<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr74-0884533612455203">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bistrian</surname><given-names>BR</given-names></name>
</person-group>. <article-title>Parenteral feeding and intensive insulin therapy</article-title>. <source>Crit Care Med</source>. <year>2010</year>;<volume>38</volume>(<issue>9</issue>):<year>1922</year>; <comment>author reply 1922-1923</comment>.</citation>
</ref>
<ref id="bibr75-0884533612455203">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyfroidt</surname><given-names>G</given-names></name>
<name><surname>Van den Berghe</surname><given-names>G</given-names></name>
</person-group>. <article-title>Parenteral feeding and intensive insulin therapy [reply]</article-title>. <source>Crit Care Med</source>. <year>2010</year>;<volume>38</volume>:<fpage>1922</fpage>-<lpage>1923</lpage>.</citation>
</ref>
<ref id="bibr76-0884533612455203">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Maerz</surname><given-names>LL</given-names></name>
<name><surname>Akhtar</surname><given-names>S</given-names></name>
</person-group>. <article-title>Perioperative glycemic management in 2011: paradigm shifts</article-title>. <source>Curr Opin Crit Care</source>. <year>2011</year>;<volume>17</volume>(<issue>4</issue>):<fpage>370</fpage>-<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr77-0884533612455203">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reeds</surname><given-names>D</given-names></name>
</person-group>. <article-title>Near-normal glycemia for critically ill patients receiving nutrition support: fact or folly</article-title>. <source>Curr Opin Gastroenterol</source>. <year>2010</year>;<volume>26</volume>(<issue>2</issue>):<fpage>152</fpage>-<lpage>155</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>